Xenon Pharmaceuticals Inc.
NASDAQ:XENE
40.84 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 9.434 | 18.437 | 32.166 | 6.829 | 0 | 0.311 | 1.803 | 15.577 | 28.37 | 27.356 | 14.308 | 6.918 |
| Cost of Revenue
| 3.541 | 105.767 | 75.463 | 50.523 | 38.845 | 6 | 25.573 | 1.114 | 2.762 | 5.903 | 6.21 | 7.32 | 0 |
| Gross Profit
| -3.541 | -96.333 | -57.026 | -18.357 | -32.016 | -6 | -25.262 | 0.689 | 12.815 | 22.467 | 21.146 | 6.988 | 6.918 |
| Gross Profit Ratio
| 0 | -10.211 | -3.093 | -0.571 | -4.688 | 0 | -81.228 | 0.382 | 0.823 | 0.792 | 0.773 | 0.488 | 1 |
| Reseach & Development Expenses
| 167.512 | 105.767 | 75.463 | 50.523 | 38.845 | 23.634 | 25.573 | 19.828 | 15.152 | 11.768 | 12.303 | 10.455 | 12.302 |
| General & Administrative Expenses
| 46.542 | 32.81 | 21.967 | 12.944 | 10.803 | 8.382 | 7.313 | 6.792 | 9.786 | 5.496 | 5.341 | 7.006 | 6.73 |
| Selling & Marketing Expenses
| -3.541 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 43.001 | 32.81 | 21.967 | 12.944 | 10.803 | 8.382 | 7.313 | 6.792 | 9.786 | 5.496 | 5.341 | 7.006 | 6.73 |
| Other Expenses
| 0 | 3.888 | 0.105 | 2.207 | 0 | 4.398 | 0 | 0 | -6.391 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 210.513 | 138.577 | 97.43 | 63.467 | 49.648 | 32.016 | 32.886 | 26.62 | 24.938 | 17.264 | 17.644 | 17.461 | 19.032 |
| Operating Income
| -214.054 | -129.143 | -78.993 | -31.301 | -42.819 | -38.016 | -32.575 | -24.817 | -9.361 | 11.106 | 9.712 | -3.153 | -12.114 |
| Operating Income Ratio
| 0 | -13.689 | -4.284 | -0.973 | -6.27 | 0 | -104.743 | -13.764 | -0.601 | 0.391 | 0.355 | -0.22 | -1.751 |
| Total Other Income Expenses Net
| 31.369 | 3.888 | 0.105 | 2.207 | 1.201 | 3.697 | 1.394 | 1.316 | -6.391 | 1.344 | 2.046 | -1.199 | 0.06 |
| Income Before Tax
| -182.685 | -125.255 | -78.888 | -29.094 | -41.618 | -34.497 | -30.704 | -22.997 | -15.752 | 13.018 | 12.032 | -4.301 | -11.992 |
| Income Before Tax Ratio
| 0 | -13.277 | -4.279 | -0.904 | -6.094 | 0 | -98.727 | -12.755 | -1.011 | 0.459 | 0.44 | -0.301 | -1.733 |
| Income Tax Expense
| -0.292 | 0.118 | -0.006 | -0.257 | -0.023 | 4.913 | -1.871 | -1.82 | -1.038 | 0 | 0.064 | 0.093 | 0.091 |
| Net Income
| -182.393 | -125.373 | -78.882 | -28.837 | -41.595 | -34.497 | -30.704 | -22.997 | -15.752 | 13.018 | 12.032 | -4.301 | -11.992 |
| Net Income Ratio
| 0 | -13.289 | -4.278 | -0.897 | -6.091 | 0 | -98.727 | -12.755 | -1.011 | 0.459 | 0.44 | -0.301 | -1.733 |
| EPS
| -2.73 | -2.07 | -1.81 | -0.83 | -1.6 | -1.78 | -1.71 | -1.48 | -1.1 | 4.11 | 0.42 | -0.47 | -1.32 |
| EPS Diluted
| -2.73 | -2.07 | -1.81 | -0.83 | -1.6 | -1.78 | -1.71 | -1.48 | -1.1 | 3.28 | 0.39 | -0.44 | -1.23 |
| EBITDA
| -210.513 | -129.143 | -78.993 | -31.301 | -40.037 | -36.214 | -33.32 | -25.269 | -9.361 | 12.412 | 10.755 | -2.223 | -10.829 |
| EBITDA Ratio
| 0 | -13.689 | -4.284 | -0.973 | -5.863 | 0 | -107.138 | -14.015 | -0.601 | 0.438 | 0.393 | -0.155 | -1.565 |